Immunostimulatory method
This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.
1. A method for preventing or treating a respiratory condition associated with one or more bacterial infectious agents in a subject, the method comprising:
administering to the respiratory tract a composition comprising a TLR2 agonist and a solubilizing agent, thereby preventing or treating the respiratory condition in the subject,
wherein the composition does not contain, nor induce production of, a peptide antigen comprising a T-helper epitope.
2. The method according to claim 1 , wherein the TLR2 agonist is selected from the group consisting of S-[2,3-bis(palmitoyloxy)propyl]cysteine (Pam2Cys), N-palmitoyl-S-[2,3-bis(palmitoyloxy) propyl] cysteine (Pam 3 Cys), S-[2,3-bis(stearoyloxy) propyl] cysteine, S-[2,3-bis(lauroyloxy) propyl] cysteine, and S-[2,3-bis(octanoyloxy) propyl] cysteine.
3. The method according to claim 2 , wherein the TLR2 agonist is Pam 2 Cys.
4. The method according to claim 1 , wherein the solubilizing agent comprises polyethyleneglycol (PEG) or a polar polypeptide.
5. The method according to claim 4 , wherein the polar polypeptide is selected from the group consisting of K4, R4, H4, E8, branched E8 and H8.
6. The method according to claim 5 , wherein the polar polypeptide is K4.
7. The method according to claim 6 , wherein the TLR2 agonist is Pam 2 Cys and wherein Pam 2 Cys is attached to K4 via at least one serine (S) residue.
8. The method according to claim 7 , wherein the composition comprises Pam 2 CysSK4.
9. The method according to claim 7 , wherein the composition comprises Pam 2 CysS2K4.
10. The method according to claim 1 , wherein the solubilizing agent comprises polyethyleneglycol (PEG).
11. The method according to claim 1 , wherein the solubilizing agent comprises polyethyleneglycol (PEG) and any one of K4, R4, H4, E8, branched E8 and H8.
12. The method according to claim 1 , wherein the composition comprises PEG-Pam 2 Cys.
13. The method according to claim 9 , wherein the composition is administered intranasally to the subject.
14. The method according to claim 9 , wherein the condition is associated with an infectious agent in the form of a bacterial infection.
15. The method according to claim 9 , wherein a TLR9 agonist is not administered.
16. The method according to claim 9 , wherein an oligodeoxynucleotide (ODN) is not administered.
17. The method according to claim 1 , wherein the composition does not comprise a peptide antigen.
18. The method according to claim 1 , wherein the composition does not comprise an antigen.
19. The method according to claim 1 , wherein the composition comprises an antigen that cannot raise an antigen specific immune response to the one or more infectious agents.
20. The method according to claim 5 , wherein composition comprises R4Pam2Cys and has the structure:
21. The method according to claim 5 , wherein the composition comprises H4Pam2Cys and has the structure:
22. The method according to claim 5 , wherein composition comprises H8Pam2Cys and has the structure:
23. The method according to claim 5 , wherein the composition comprises E8Pam2Cys and has the structure:
24. The method according to claim 5 , wherein the composition comprises branched E8Pam2Cys and has the structure: